X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SB 11285 is Spring Bank’s intravenously (IV)-administered STING agonist product candidate that is currently being evaluated in a Phase 1a/1b clinical trial as a monotherapy and in combination with Roche’s PD-L1 checkpoint inhibitor (Tecentriq®).
Lead Product(s): SB 11285,Atezolizumab
Therapeutic Area: Oncology Product Name: SB 11285
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2020
Details:
Safety Review Committee for IV SB 11285 Phase 1a/1b trial recommends dose escalation to next planned monotherapy dose level and initiation of first co-administration dose level with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq®).
Lead Product(s): SB 11285
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2020
Details:
Trial in progress poster will be presented for the Phase 1a/1b trial of the company’s intravenously-administered STING agonist candidate, SB 11285, at the American Society of Clinical Oncology (ASCO) Annual Meeting.
Lead Product(s): SB 11285,Nivolumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 20, 2020
Details:
New clinical collaboration with Roche (SIX:RO, ROG), will explore the co-administration of SB 11285 with Roche’s PD-L1 checkpoint inhibitor Tecentriq in patients with advanced solid tumors.
Lead Product(s): SB 11285
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 25, 2020
Details:
The company based the decision on safety information after unexpected serious adverse events, including one patient death in its Phase IIb CATALYST trial.
Lead Product(s): Inarigivir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
